SCHEMBL5583428

SCHEMBL5583428

COc1cccc(CNc2ccc3oc(C(=O)O)cc3c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.58
MAPT P10636 3/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
MMP13 P45452 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
HDAC4 P56524 1/20 0.47
MEF2D Q14814 1/20 0.47
PPARA Q07869 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
APEX1 P27695 1/20 0.46
FFAR1 O14842 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL212028 0.83 HDAC4 (0.57) HIF1AMAPTMEN1KMT2AKDM4E
SCHEMBL5583397 0.82 DHFR (0.53) HIF1AMEN1KMT2ALMNATP53
SCHEMBL3558423 0.81 TUBB4A (0.54) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL3560484 0.81 LMNA (0.56) HIF1AMAPTMEN1KMT2AKDM4E
SCHEMBL31168774 0.78 RAB9A (0.52) HIF1AMAPTMEN1KMT2AKDM4E
SCHEMBL11421875 0.78 HIF1A (0.72) HIF1AMAPTMEN1KMT2AKDM4E
SCHEMBL31168785 0.77 MAPT (0.56) HIF1AMAPTMEN1KMT2ALMNA
SCHEMBL14043860 0.77 HIF1A (0.71) HIF1AMAPTMEN1KMT2AKDM4E
SCHEMBL335319 0.77 KDM4E (0.66) KDM4EALDH1A1LMNATP53TAS1R3
SCHEMBL29527237 0.77 KDM4E (0.66) KDM4EALDH1A1LMNATP53TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 HIF1A 437/4885MAPT 3612/4885MEN1 2386/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 HIF1A 648/4885MAPT 3905/4885MEN1 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.